


miR-1246 as biomarker and radiosensitization target



**Figure S1.** Establishment and verification of radioresistant NSCLC cell lines. A. Both A549 and PC9 cells were irradiated according to procedure described in the Method part and sublines were renamed as A549-R and PC9-R respectively. B. The survival curves of RR and their parental cell lines after irradiation (n=3). They were irradiated with 0, 2, 4, 6, 8, 10 Gy and colonies formed after 14 days. \*, p<0.05; \*\*, p<0.01; \*\*\*, p<0.001. IR: irradiation. Gy: grayunit.

## miR-1246 as biomarker and radiosensitization target

**Table S1.** Radiosensitive Parameters of Respective Cell Lines

Parameter	D0	SF2	SER10
A549	2.75	0.52	1
A549-R	3.52	0.61	0.77
PC9	2.55	0.47	1
PC9-R	3.27	0.57	0.79
A549-ago-nc	2.86	0.51	1
A549-ago	3.39	0.65	0.82
PC9-ago-nc	2.65	0.48	1
PC9-ago	3.07	0.63	0.76
A549-R-anta-nc	3.68	0.63	1
A549-R-anta	2.61	0.50	1.25
PC9-R-anta-nc	3.00	0.55	1
PC9-R-anta	2.58	0.46	1.18
A549-ago-nc+ctrl	2.84	0.53	1
A549-ago-nc+rapamicin	3.43	0.65	0.89
A549-ago+ctrl	3.52	0.63	0.88
A549-ago+rapamicin	4.25	0.74	0.75
PC9-ago-nc+ctrl	2.39	0.47	1
PC9-ago-nc+rapamicin	3.32	0.60	0.79
PC9-ago+ctrl	3.33	0.61	0.78
PC9-ago+rapamicin	4.25	0.71	0.65
A549-R-anta-nc+ctrl	3.49	0.60	1
A549-R-anta-nc+CQ	2.72	0.48	1.20
A549-R-anta+ctrl	2.50	0.43	1.26
A549-R-anta+CQ	2.39	0.38	1.41
PC9-R-anta-nc+ctrl	3.98	0.75	1
PC9-R-anta-nc+CQ	2.84	0.54	1.22
PC9-R-anta+ctrl	2.77	0.48	1.27
PC9-R-anta+CQ	2.17	0.41	1.53
A549-ago-nc	2.94	0.56	1.22
A549-ago	3.56	0.65	1
A549-ago+mTOR	2.94	0.56	1.19
A549-ago+CQ	3.00	0.50	1.28
PC9-ago-nc	2.69	0.48	1.28
PC9-ago	3.26	0.55	1
PC9-ago+mTOR	2.70	0.49	1.21
PC9-ago+CQ	2.48	0.46	1.39

ago: agomir, anta: antagomir; D0, dose to reduce survival to 37% of its value; SF2, surviving fraction at 2 Gy; SER10, sensitizer enhancement ratio at 10% survival.

## miR-1246 as biomarker and radiosensitization target

**Table S2.** Probe and primer information

Name	Sequence (5'-3')
Primers for qRT-PCR	
miRNA universal R	GTGCAGGGTCCGAGGT
miR-1246-F	CGCAGAATGGATTTTTGGAG
miR-1246-RT	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAC
miR-1908-5p-F	ATAATAACGCGGGGACGG
miR-1908-5p-RT	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAC
miR-1915-3p-F	GCGCTGGAAGACTAGTGATTTTG
miR-1915-3p-RT	CTCAACTGGTGTCTGGAGTCCGGCAATTCAGTTGAGCCC GCCG
miR-25-5p-F	CGCCTCTTTGTTATCTAGCTGT
miR-25-5p-RT	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAC
miR-638-F	ATCCAGTGC GT TCGTG
miR-638-RT	GTCGTATCCAGTGC GT TCGTGAGTCCGGCAATTCGCACTGGATA
miR-762-F	CGGGGCAGGGACAGAG
miR-762-RT	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAC
miR-7977-F	TATAGATAGTGTGGCCGGCAG
miR-7977-RT	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAC
miR-4485-F	AGUAACGGCCCGGUAC
miR-4485-RT	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAC
U6-F	CTCGCTTCGGCAGCAC
U6-R	AACGCTTCACGAATTTGCGT
mTOR-F	AAGCCGCGGAACCTC
mTOR-R	GGCATCTGAGCTGAAAACCA
ATG2B-F	GTGGATCTGAGGAGGAGAC
ATG2B-R	ACACTTCGGATTTGTAAACC
DRAM-F	GTCCCCTCCTCTTGGTGACCTG
DRAF-R	CTGTCCATTCACAGATCGCACTCA
ATG12-F	GATGTCTCCCCAGAAACAAC
ATG12-R	CACCCCTACTCGGATGC
ATG10-F	TACGCAACAGGAACATCCA
ATG10-R	AACAACCTGGCCCTACAATGC
ATG4D-F	GAGGAAATTGAGGTATAGAGAGGC
ATG4D-R	AACGCCCAAATAAACTAACTACG
YY1-F	CCTGGCATTGACCTCTCAGATCCCA
YY1-R	GGGCAAGCTATTGTTCTTGAGCA
GAPDH-F	GGGAGCCAAAAGGGTCATCATCTC
GAPDH-R	CCATGCCAGTGAGCTTCCCGTTC
Primers for ChIP-PCR	
Site A-F	CATTTTATTTTAACTCTGAGTCCATG
Site A-R	GGATACAACAAAGCCATCAGTGT
Site B-F	AACCTGAGTGGTTTGTCTGAACC
Site B-R	ATGTGATGATTTATTGCTTTGGAG
Site C-F	CGAAAATATGAATAAGGATAAGG
Site C-R	CAAGATTCAGAAAATGGTGCC
Site D-F	TGAATCTTGAAGAGATGGAAGA
Site D-R	ACACTCTAGGTCTCCTCTGGCC
Site E-F	CAGTGTAGCGTACTGAGAAGCA
Site E-R	CCTCTTTGTGGAGCAACTTTTCT
Site F-F	GCAAAGCAGGAAATGGAAAATC
Site F-R	GTTCCCTTGATGTGGATTATTCTC

## miR-1246 as biomarker and radiosensitization target

### Probes for EMSA

mut-A	TTAATCTGAGTCCATGTTGGCA
mut-B	GTAAAAAATGGGTCCATAG
mut-C	CTTCTGGCCACCATTCTGA
mut-D	TGGAAGAGATGGAAGAAA
mut-E	GATTCACAATGGCCATGCG
mut-F	CAGATGGCCATCATTCGTC


### Probes for ISH

miR-1246 DIG-CCTGCTCCAAAAATCCATT-DIG

### Probes for FISH


CDR1as DIG-GGTGCCATCGGAAACCCTGGATATTGCAGACACTG-DIG.

F: forward, R: reverse, RT, reverse-transcription, mut: mutant.




**Figure S2.** Verification of differentially expressed miRNA by qRT-PCR. A. Heat map of eight miRNAs (5 up-regulated, 2 down-regulated, and 1 non-significant) based on the miRNA microarray results by qPCR (n=3). Yellow represented relatively high expression while blue represented relatively low expression. B, C. Relative expression of these eight miRNAs in both A549 and PC9 cell lines. Data were shown as the means  $\pm$  SD. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ; ns, no significant. D. The correlation of qRT-PCR and microarray results. Red represented the results in A549 and A549-R cell lines (Pearson  $r = 0.897$ ,  $p = 0.04$ ) while blue represented the results in PC9 and PC9-R cell lines (Pearson  $r = 0.921$ ,  $p = 0.01$ ).

miR-1246 as biomarker and radiosensitization target



**Figure S3.** Downregulated miR-1246 inhibits autophagy in NSCLC cells. A. Downregulated miR-1246 decreased LC-II expression and increased SQSTM1/p62 expression. B. Downregulated miR-1246 decreased autophagic vacuoles accumulation under electron microscopy observations. Red arrow: autophagic vacuoles. C. Downregulated miR-1246 decreased autophagosome accumulation by immunofluorescence detection. Red arrow: autophagic vacuoles. anta: antagomir, nc: negative control. n=3 per group.

miR-1246 as biomarker and radiosensitization target



**Figure S4.** Correlation of miR-1246 with clinicopathologic factors and other key genes in TCGA dataset. LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma. Data were shown as the means  $\pm$  SD.